Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2014

01.11.2014 | Clinical Study

Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters

verfasst von: Asim K. Bag, Phillip C. Cezayirli, Jake J. Davenport, Santhosh Gaddikeri, Hassan M. Fathallah-Shaykh, Alan Cantor, Xiaosi S. Han, Louis B. Nabors

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to evaluate if peritumoral (PT) perfusion parameters obtained from dynamic susceptibility weighted contrast enhanced perfusion MRI can predict overall survival (OS) and progression free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM). Twenty-eight newly diagnosed GBM patients, who were treated with resection followed by concurrent chemoradiation and adjuvant chemotherapy, were included in this study. Evaluated perfusion parameters were pre- and post-treatment PT relative cerebral blood volume (rCBV) and relative cerebral blood flow (rCBF). Proportional hazard analysis was used to assess the relationship OS, PFS and perfusion parameters. Kaplan–Meier survival estimates and log-rank test were used to characterize and compare the patient groups with high and low perfusion parameter values in terms of OS and PFS. Pretreatment PT rCBV and rCBF were not associated with OS and PFS whereas there was statistically significant association of both posttreatment PT rCBV and rCBF with OS and posttreatment rCBV with PFS (association of PFS and posttreatment rCBF was not statistically significant). Neither the Kaplan–Meier survival estimates nor the log-rank test demonstrated any differences in OS between high and low pretreatment PT rCBV values and rCBF values; however, high and low post-treatment PT rCBV and rCBF values did demonstrate statistically significant difference in OS and PFS. Our study found posttreatment, not pretreatment, PT perfusion parameters can be used to predict OS and PFS in patients with newly diagnosed GBM.
Literatur
1.
Zurück zum Zitat Kleihues P, Burger PC, Aldape KD et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumors of the central nervous system. IARC Press, Lyon, pp 33–49 Kleihues P, Burger PC, Aldape KD et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumors of the central nervous system. IARC Press, Lyon, pp 33–49
2.
Zurück zum Zitat Mangla R, Singh G, Ziegelitz D, Milano MT, Korones DN, Zhong J, Ekholm SE (2010) Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 256:575–584. doi:10.1148/radiol.10091440 PubMedCrossRef Mangla R, Singh G, Ziegelitz D, Milano MT, Korones DN, Zhong J, Ekholm SE (2010) Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 256:575–584. doi:10.​1148/​radiol.​10091440 PubMedCrossRef
3.
Zurück zum Zitat Choi YJ, Kim HS, Jahng GH, Kim SJ, Suh DC (2013) Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging. Acta Radiol 54:448–454. doi:10.1177/0284185112474916 PubMedCrossRef Choi YJ, Kim HS, Jahng GH, Kim SJ, Suh DC (2013) Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging. Acta Radiol 54:448–454. doi:10.​1177/​0284185112474916​ PubMedCrossRef
4.
Zurück zum Zitat Stupp R, Mason WP, van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330 CrossRef Stupp R, Mason WP, van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The N Engl J Med 352:987–996. doi:10.​1056/​NEJMoa043330 CrossRef
5.
Zurück zum Zitat Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 24:1989–1998PubMed Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 24:1989–1998PubMed
6.
Zurück zum Zitat Cha S, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS, Nelson SJ, Dillon WP (2007) Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am J Neuroradiol 28:1078–1084. doi:10.3174/ajnr.A0484 PubMedCrossRef Cha S, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS, Nelson SJ, Dillon WP (2007) Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am J Neuroradiol 28:1078–1084. doi:10.​3174/​ajnr.​A0484 PubMedCrossRef
7.
Zurück zum Zitat Cha S (2006) Update on brain tumor imaging: from anatomy to physiology. Am J Neuroradiol 27:475–487PubMed Cha S (2006) Update on brain tumor imaging: from anatomy to physiology. Am J Neuroradiol 27:475–487PubMed
8.
Zurück zum Zitat Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z (2009) Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? Am J Neuroradiol 30:681–688. doi:10.3174/ajnr.A1465 PubMedCrossRef Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z (2009) Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? Am J Neuroradiol 30:681–688. doi:10.​3174/​ajnr.​A1465 PubMedCrossRef
9.
Zurück zum Zitat Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, Coons SW, Nakaji P, Yeh RF, Debbins J, Heiserman JE (2009) Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. Am J Neuroradiol 30:552–558. doi:10.3174/ajnr.A1377 PubMedCrossRef Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, Coons SW, Nakaji P, Yeh RF, Debbins J, Heiserman JE (2009) Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. Am J Neuroradiol 30:552–558. doi:10.​3174/​ajnr.​A1377 PubMedCrossRef
11.
Zurück zum Zitat Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A, Akter M, Hayashida Y, Toya R, Oya N, Awai K, Iyama K, Kuratsu JI, Yamashita Y (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. Am J Neuroradiol 29:1505–1510. doi:10.3174/ajnr.A1121 PubMedCrossRef Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A, Akter M, Hayashida Y, Toya R, Oya N, Awai K, Iyama K, Kuratsu JI, Yamashita Y (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. Am J Neuroradiol 29:1505–1510. doi:10.​3174/​ajnr.​A1121 PubMedCrossRef
12.
Zurück zum Zitat Rollin N, Guyotat J, Streichenberger N, Honnorat J, Minh VAT, Cotton F (2006) Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 48:150–159. doi:10.1007/s00234-005-0030-7 PubMedCrossRef Rollin N, Guyotat J, Streichenberger N, Honnorat J, Minh VAT, Cotton F (2006) Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 48:150–159. doi:10.​1007/​s00234-005-0030-7 PubMedCrossRef
13.
Zurück zum Zitat Schmainda KM, Rand SD, Joseph AM, Lund R, Ward BD, Pathak AP, Ulmer JL, Badruddoja MA, Krouwer HG (2004) Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. Am J Neuroradiol 25:1524–1532PubMed Schmainda KM, Rand SD, Joseph AM, Lund R, Ward BD, Pathak AP, Ulmer JL, Badruddoja MA, Krouwer HG (2004) Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. Am J Neuroradiol 25:1524–1532PubMed
15.
Zurück zum Zitat Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G (2004) Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. Am J Neuroradiol 25:746–755PubMed Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G (2004) Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. Am J Neuroradiol 25:746–755PubMed
16.
Zurück zum Zitat Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D, Johnson G (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490–498. doi:10.1148/radiol.2472070898 PubMedCrossRefPubMedCentral Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D, Johnson G (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490–498. doi:10.​1148/​radiol.​2472070898 PubMedCrossRefPubMedCentral
19.
Zurück zum Zitat Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, Cha S (2009) Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 253:486–496. doi:10.1148/radiol.2532090007 PubMedCrossRefPubMedCentral Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, Cha S (2009) Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 253:486–496. doi:10.​1148/​radiol.​2532090007 PubMedCrossRefPubMedCentral
20.
Zurück zum Zitat Gasparetto EL, Pawlak MA, Patel SH, Huse J, Woo JH, Krejza J, Rosenfeld MR, O’Rourke DM, Lustig R, Melhem ER, Wolf RL (2009) Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology 250:887–896. doi:10.1148/radiol.2502071444 PubMedCrossRef Gasparetto EL, Pawlak MA, Patel SH, Huse J, Woo JH, Krejza J, Rosenfeld MR, O’Rourke DM, Lustig R, Melhem ER, Wolf RL (2009) Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology 250:887–896. doi:10.​1148/​radiol.​2502071444 PubMedCrossRef
22.
Zurück zum Zitat De Belder FE, Oot AR, Van Hecke W, Venstermans C, Menovsky T, Van Marck V, Van Goethem J, Van den Hauwe L, Vandekerckhove M, Parizel PM (2012) Diffusion tensor imaging provides an insight into the microstructure of meningiomas, high-grade gliomas, and peritumoral edema. J Comput Assist Tomogr 36:577–582. doi:10.1097/RCT.0b013e318261e913 PubMedCrossRef De Belder FE, Oot AR, Van Hecke W, Venstermans C, Menovsky T, Van Marck V, Van Goethem J, Van den Hauwe L, Vandekerckhove M, Parizel PM (2012) Diffusion tensor imaging provides an insight into the microstructure of meningiomas, high-grade gliomas, and peritumoral edema. J Comput Assist Tomogr 36:577–582. doi:10.​1097/​RCT.​0b013e318261e913​ PubMedCrossRef
24.
25.
Zurück zum Zitat Blasel S, Franz K, Ackermann H, Weidauer S, Zanella F, Hattingen E (2011) Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery. J Neuro-oncology 103:575–584. doi:10.1007/s11060-010-0421-4 CrossRef Blasel S, Franz K, Ackermann H, Weidauer S, Zanella F, Hattingen E (2011) Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery. J Neuro-oncology 103:575–584. doi:10.​1007/​s11060-010-0421-4 CrossRef
26.
Zurück zum Zitat Server A, Orheim TE, Graff BA, Josefsen R, Kumar T, Nakstad PH (2011) Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis. Neuroradiology 53:319–330. doi:10.1007/s00234-010-0740-3 PubMedCrossRef Server A, Orheim TE, Graff BA, Josefsen R, Kumar T, Nakstad PH (2011) Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis. Neuroradiology 53:319–330. doi:10.​1007/​s00234-010-0740-3 PubMedCrossRef
27.
Zurück zum Zitat Lehmann P, Saliou G, de Marco G, Monet P, Souraya SE, Bruniau A, Vallee JN, Ducreux D (2012) Cerebral peritumoral oedema study: does a single dynamic MR sequence assessing perfusion and permeability can help to differentiate glioblastoma from metastasis? Eur J Radiol 81:522–527. doi:10.1016/j.ejrad.2011.01.076 PubMedCrossRef Lehmann P, Saliou G, de Marco G, Monet P, Souraya SE, Bruniau A, Vallee JN, Ducreux D (2012) Cerebral peritumoral oedema study: does a single dynamic MR sequence assessing perfusion and permeability can help to differentiate glioblastoma from metastasis? Eur J Radiol 81:522–527. doi:10.​1016/​j.​ejrad.​2011.​01.​076 PubMedCrossRef
29.
Zurück zum Zitat Thomsen H, Steffensen E, Larsson EM (2012) Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas. Acta Radiol 53:95–101. doi:10.1258/ar.2011.110242 PubMedCrossRef Thomsen H, Steffensen E, Larsson EM (2012) Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas. Acta Radiol 53:95–101. doi:10.​1258/​ar.​2011.​110242 PubMedCrossRef
30.
Zurück zum Zitat Law M, Young R, Babb J, Rad M, Sasaki T, Zagzag D, Johnson G (2006) Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. Am J Neuroradiol 27:1975–1982PubMed Law M, Young R, Babb J, Rad M, Sasaki T, Zagzag D, Johnson G (2006) Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. Am J Neuroradiol 27:1975–1982PubMed
31.
Zurück zum Zitat Parikh AH, Smith JK, Ewend MG, Bullitt E (2004) Correlation of MR perfusion imaging and vessel tortuosity parameters in assessment of intracranial neoplasms. Technol Cancer Res Treat 3:585–590PubMedCrossRefPubMedCentral Parikh AH, Smith JK, Ewend MG, Bullitt E (2004) Correlation of MR perfusion imaging and vessel tortuosity parameters in assessment of intracranial neoplasms. Technol Cancer Res Treat 3:585–590PubMedCrossRefPubMedCentral
32.
Zurück zum Zitat Kleihues P, Burger PC, Aldape KD et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumors of the central nervous system. IARC Press, Lyon, pp 33–49 Kleihues P, Burger PC, Aldape KD et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumors of the central nervous system. IARC Press, Lyon, pp 33–49
34.
Zurück zum Zitat Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. Am J Neuroradiol 27:859–867PubMed Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. Am J Neuroradiol 27:859–867PubMed
35.
Zurück zum Zitat Wetzel SG, Cha S, Johnson G, Lee P, Law M, Kasow DL, Pierce SD, Xue X (2002) Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 224:797–803PubMedCrossRef Wetzel SG, Cha S, Johnson G, Lee P, Law M, Kasow DL, Pierce SD, Xue X (2002) Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 224:797–803PubMedCrossRef
36.
Zurück zum Zitat Young R, Babb J, Law M, Pollack E, Johnson G (2007) Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. J Magn Reson Imaging 26:1053–1063. doi:10.1002/jmri.21064 PubMedCrossRef Young R, Babb J, Law M, Pollack E, Johnson G (2007) Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. J Magn Reson Imaging 26:1053–1063. doi:10.​1002/​jmri.​21064 PubMedCrossRef
37.
Zurück zum Zitat Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shapiro WR, Liu S, Karis JP, Smith KA, Coons SW, Nakaji P, Spetzler RF, Feuerstein BG, Debbins J, Baxter LC (2012) Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro-oncology 14:919–930. doi:10.1093/neuonc/nos112 PubMedCrossRefPubMedCentral Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shapiro WR, Liu S, Karis JP, Smith KA, Coons SW, Nakaji P, Spetzler RF, Feuerstein BG, Debbins J, Baxter LC (2012) Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro-oncology 14:919–930. doi:10.​1093/​neuonc/​nos112 PubMedCrossRefPubMedCentral
38.
39.
Zurück zum Zitat Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR, Fitzek MM, Chiocca EA, Rabinov JD, Csavoy AN, Rosen BR, Hochberg FH, Schaefer PW, Gonzalez RG (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. Am J Neuroradiol 25:214–221PubMed Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR, Fitzek MM, Chiocca EA, Rabinov JD, Csavoy AN, Rosen BR, Hochberg FH, Schaefer PW, Gonzalez RG (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. Am J Neuroradiol 25:214–221PubMed
40.
Zurück zum Zitat Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging–prediction of patient clinical response. Radiology 238:658–667. doi:10.1148/radiol.2382042180 PubMedCrossRef Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging–prediction of patient clinical response. Radiology 238:658–667. doi:10.​1148/​radiol.​2382042180 PubMedCrossRef
41.
Zurück zum Zitat Mills SJ, Patankar TA, Haroon HA, Baleriaux D, Swindell R, Jackson A (2006) Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? Am J Neuroradiol 27:853–858PubMed Mills SJ, Patankar TA, Haroon HA, Baleriaux D, Swindell R, Jackson A (2006) Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? Am J Neuroradiol 27:853–858PubMed
42.
Zurück zum Zitat Haris M, Husain N, Singh A, Husain M, Srivastava S, Srivastava C, Behari S, Rathore RK, Saksena S, Gupta RK (2008) Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma. J Comput Assist Tomogr 32:955–965. doi:10.1097/RCT.0b013e31816200d1 PubMedCrossRef Haris M, Husain N, Singh A, Husain M, Srivastava S, Srivastava C, Behari S, Rathore RK, Saksena S, Gupta RK (2008) Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma. J Comput Assist Tomogr 32:955–965. doi:10.​1097/​RCT.​0b013e31816200d1​ PubMedCrossRef
43.
Zurück zum Zitat Majchrzak K, Kaspera W, Szymas J, Bobek-Billewicz B, Hebda A, Majchrzak H (2013) Markers of angiogenesis (CD31, CD34, rCBV) and their prognostic value in low-grade gliomas. Neurol Neurochir Pol 47:325–331. doi:10.5114/ninp.2013.36757 PubMed Majchrzak K, Kaspera W, Szymas J, Bobek-Billewicz B, Hebda A, Majchrzak H (2013) Markers of angiogenesis (CD31, CD34, rCBV) and their prognostic value in low-grade gliomas. Neurol Neurochir Pol 47:325–331. doi:10.​5114/​ninp.​2013.​36757 PubMed
44.
Zurück zum Zitat Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. doi:10.1056/NEJMoa1308573 PubMedCrossRefPubMedCentral Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. doi:10.​1056/​NEJMoa1308573 PubMedCrossRefPubMedCentral
Metadaten
Titel
Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters
verfasst von
Asim K. Bag
Phillip C. Cezayirli
Jake J. Davenport
Santhosh Gaddikeri
Hassan M. Fathallah-Shaykh
Alan Cantor
Xiaosi S. Han
Louis B. Nabors
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2014
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1560-9

Weitere Artikel der Ausgabe 2/2014

Journal of Neuro-Oncology 2/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.